ENTPD1 and cancer: Further exploration of targeted inhibition of CD39-CD73-eAdo/A2aR alone or combined with other immunotherapy, radiotherapy, and chemotherapy in treating various cancer types and developing effective clinical therapeutic drugs are continuous research hotspots in this field.